Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.TA)

TEVA.TA on Tel Aviv Stock Exchange

19,140.00
30 Aug 2016
Change (% chg)

-160.00₪ (-0.83%)
Prev Close
19,300.00₪
Open
19,220.00₪
Day's High
19,220.00₪
Day's Low
19,120.00₪
Volume
69,895
Avg. Vol
489,809
52-wk High
25,930.00₪
52-wk Low
18,940.00₪

TEVA.TA

Chart for TEVA.TA

About

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000... (more)

Overall

Beta: 1.02
Market Cap(Mil.): ₪196,513.50
Shares Outstanding(Mil.): 1,014.36
Dividend: 128.35
Yield (%): 2.74

Financials

  TEVA.TA Industry Sector
P/E (TTM): 34.17 36.93 36.63
EPS (TTM): 5.67 -- --
ROI: 4.12 14.69 14.12
ROE: 5.06 15.48 15.04

Mylan to launch generic EpiPen at half the price of original

Mylan NV said it would launch the first generic version of its allergy auto-injector EpiPen for $300, half the price of the branded product, the drugmaker's second step in less than a week to counter the backlash over the product's steep price.

Aug 29 2016

Mylan to launch generic EpiPen at half the price of original

Mylan NV said it would launch the first generic version of its allergy auto-injector EpiPen for $300, half the price of the branded product, the drugmaker's second step in less than a week to counter the backlash over the product's steep price. | Video

Aug 29 2016

UPDATE 7-Mylan to launch generic EpiPen at half the price of original

* Launch raised as many questions as solutions-Democratic senator

Aug 29 2016

BRIEF-Moody's says Teva's loss of two copaxone patents is credit negative

* Moody's on Teva Pharmaceutical - there is no change to Teva Pharmaceutical Industries LTD Baa2 senior unsecured rating or stable outlook Source text for Eikon:

Aug 25 2016

Mylan wins round in fight with Teva over multiple sclerosis drug

WASHINGTON Pharmaceutical company Mylan NV has won a round in its fight with Teva Pharmaceutical Industries Ltd at the U.S. Patent and Trademark Office, which said on Wednesday that two patents for the multiple sclerosis drug Copaxone sold by Teva were, after a review process, considered unpatentable.

Aug 24 2016

UPDATE 2-Mylan wins round in fight with Teva over multiple sclerosis drug

WASHINGTON, Aug 24 Pharmaceutical company Mylan NV has won a round in its fight with Teva Pharmaceutical Industries Ltd at the U.S. Patent and Trademark Office, which said on Wednesday that two patents for the multiple sclerosis drug Copaxone sold by Teva were, after a review process, considered unpatentable.

Aug 24 2016

UPDATE 1-Mylan wins round in fight with Teva over multiple sclerosis drug

WASHINGTON, Aug 24 Pharmaceutical company Mylan NV has won a round in its fight with Teva Pharmaceutical Industries Ltd at the U.S. Patent and Trademark Office, which said on Wednesday that two patents for the multiple sclerosis drug Copaxone sold by Teva were, after a review process, considered unpatentable.

Aug 24 2016

BRIEF-Teva confirms PTAB's decisions on two patents in IPR challenge to Copaxone

* Teva confirms PTAB's decisions on two patents in IPR challenge to Copaxone 40 mg

Aug 24 2016

BRIEF-Mylan invalidates two of Teva's Copaxone patents

* Mylan invalidates two of Teva's Copaxone 40 mg/ml patents via U.S. Patent and Trademark Office's Inter Partes Review proceeding

Aug 24 2016

BRIEF- European Commission has granted Teva Pharmaceutical marketing authorization for cinqaero in 28 countries

* European Commission has granted marketing authorization for Cinqaero (reslizumab) in 28 countries of European Union in addition to Norway

Aug 18 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : New Constructs, LLC
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : Stock Traders Daily
$20.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.